Ligand Pharmaceuticals announced the launch of Pelthos Therapeutics, a biopharmaceutical company. Pelthos is a wholly owned subsidiary of Ligand. Pelthos is committed to commercializing therapeutic products to help patients impacted by diseases with limited treatment options.

The company's lead product is ZELSUVMI topical gel, 10.3%, for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. ZELSUVMI is expected to be available in the U.S. in late 2024.